Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
free free
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll A comprehensive map of the mTOR signaling network Caron E; Ghosh S; Matsuoka Y; Ashton-Beaucage D; Therrien M; Lemieux S; Perreault C; Roux PP; Kitano HMol Syst Biol 2010[Dec]; 6 (ä): 453The mammalian target of rapamycin (mTOR) is a central regulator of cell growth and proliferation. mTOR signaling is frequently dysregulated in oncogenic cells, and thus an attractive target for anticancer therapy. Using CellDesigner, a modeling support software for graphical notation, we present herein a comprehensive map of the mTOR signaling network, which includes 964 species connected by 777 reactions. The map complies with both the systems biology markup language (SBML) and graphical notation (SBGN) for computational analysis and graphical representation, respectively. As captured in the mTOR map, we review and discuss our current understanding of the mTOR signaling network and highlight the impact of mTOR feedback and crosstalk regulations on drug-based cancer therapy. This map is available on the Payao platform, a Web 2.0 based community-wide interactive process for creating more accurate and information-rich databases. Thus, this comprehensive map of the mTOR network will serve as a tool to facilitate systems-level study of up-to-date mTOR network components and signaling events toward the discovery of novel regulatory processes and therapeutic strategies for cancer.|*Gene Regulatory Networks[MESH]|*Protein Interaction Mapping[MESH]|*Signal Transduction[MESH]|Antineoplastic Agents/pharmacology/therapeutic use[MESH]|Humans[MESH]|Models, Biological[MESH]|Neoplasms/drug therapy[MESH]|Sirolimus/pharmacology/therapeutic use[MESH]|Systems Biology[MESH]|TOR Serine-Threonine Kinases/*metabolism[MESH] |